In a phase Ib/II clinical trial, the combination of margetuximab and pembrolizumab demonstrated synergistic anti-tumor activity, especially in tumors with low HER2 expression or in patients with low CD16A binding alleles (42). This evidence concerns the gene ERBB2 and neoplasm.